alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › hypothesis

hypothesis

8 studies tagged hypothesis, dated 2005-02-17 to 2026-10-13. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. From Hypothesis to Clinical Validation: A Bibliometric Mapping of Immunotherapy for Neurodegenerative Proteinopathies (2000-2025) 2026-10-13
  2. ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer's Disease 2022-04-26
  3. Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease 2021-05-31

Studies

8 studies carry this tag.

Date range

2005 to 2026

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 2
  • CNS & neurological disorders drug targets 1
  • Frontiers in neuroscience 1
  • Neurobiology of aging 1
  • Neuron 1

7 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. From Hypothesis to Clinical Validation: A Bibliometric Mapping of Immunotherapy for Neurodegenerative Proteinopathies (2000-2025)

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. CNS & neurological disorders drug targets 2026-10-13 Treatments

    Perhaps the most notable signal is that this accumulated progress now appears to be extending beyond Alzheimer's disease: thematic patterns suggest the same immunotherapeutic logic is beginning to extend toward Parkinson's disease and other proteinopathies.

  2. ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Frontiers in neuroscience 2022-04-26 Treatments

    Alzheimer's disease (AD) is an age-related neurodegenerative disease that affects 50 million people worldwide, with 10 million new cases occurring each year.

  3. Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2021-05-31 Treatments

    Numerous clinical trials of anti-amyloid beta (Aβ) immunotherapy in Alzheimer's disease have been performed.

  4. On the origin of proteins in human drusen: The meet, greet and stick hypothesis

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Progress in retinal and eye research 2018-12-17 Brain scans and imaging

    Retinal drusen formation is not only a clinical hallmark for the development of age-related macular degeneration (AMD) but also for other disorders, such as Alzheimer's disease and renal diseases.

  5. The antimicrobial protection hypothesis of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2018-10-09 Risk genes beyond APOE

    Mounting data link elevated brain microbe levels with AD.

  6. Calcium hypothesis of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Pflugers Archiv : European journal of physiology 2009-10-01 Risk genes beyond APOE

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder caused by an increase in amyloid metabolism.

  7. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuron 2008-11-01 Risk genes beyond APOE

    Alzheimer's disease is characterized by abnormal elevation of Abeta peptide and abnormal hyperphosphorylation of the tau protein.

  8. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neurobiology of aging 2005-02-17 Genetics

    Clinical and epidemiological studies have found that type 2 diabetes, and hyperinsulinaemia, increased the risk of developing Alzheimer's disease (AD) in the elderly.

All topic tags with their study counts